Total Payments
$278,989
2023 Payments
$277,583
Companies
6
Transactions
15
Payment Breakdown by Category
Research$278,602 (99.9%)
Food & Beverage$387.71 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $278,602 | 7 | 99.9% |
| Food and Beverage | $387.71 | 8 | 0.1% |
Payments by Type
Research
$278,602
7 transactions
General
$387.71
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $277,471 | 5 | $0 (2023) |
| Eli Lilly and Company | $1,131 | 2 | $0 (2018) |
| Alkermes, Inc. | $142.34 | 2 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $115.66 | 1 | $0 (2018) |
| ViiV Healthcare Company | $112.24 | 4 | $0 (2023) |
| Allergan Inc. | $17.47 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $277,583 | 9 | PFIZER INC. ($277,471) |
| 2019 | $17.34 | 1 | Alkermes, Inc. ($17.34) |
| 2018 | $340.66 | 2 | Eli Lilly and Company ($225.00) |
| 2017 | $1,048 | 3 | Eli Lilly and Company ($906.02) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $7,727.58 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 11/23/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: HIV | ||||||
| 10/18/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $34.87 | General |
| Category: HIV | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $139,594.57 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $3,888.63 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $85,208.73 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/17/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $29.03 | General |
| Category: HIV | ||||||
| 07/27/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: HIV | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $41,051.07 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 07/25/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: CNS | ||||||
| 05/07/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $115.66 | General |
| Category: CNS | ||||||
| 01/15/2018 | Eli Lilly and Company | — | — | In-kind items and services | $225.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | ||||||
| 05/11/2017 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CNS | ||||||
| 04/10/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/13/2017 | Eli Lilly and Company | — | — | In-kind items and services | $906.02 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $277,471 | 5 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $906.02 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | Eli Lilly and Company | $225.00 | 1 |
About Dr. Paul Eder, M.D
Dr. Paul Eder, M.D is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1104074020.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Eder, M.D has received a total of $278,989 in payments from pharmaceutical and medical device companies, with $277,583 received in 2023. These payments were reported across 15 transactions from 6 companies. The most common payment nature is "" ($278,602).
Ad
Practice Information
- Specialty Psychiatry
- Location New York, NY
- Active Since 09/04/2008
- Last Updated 10/01/2012
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1104074020
Products in Payments
- ZAVZPRET (Drug) $277,471
- Aristada 441 mg (Drug) $125.00
- LATUDA (Drug) $115.66
- RUKOBIA (Drug) $112.24
- TEFLARO (Drug) $17.47
- ARISTADA (Drug) $17.34
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in New York
Dr. Manish Zinzuvadia, M.d, M.D
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Jianping Chen, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Ulla Laakso, Md, MD
Psychiatry — Payments: $957,236
Psychiatry $957,236
Dr. Kerry Sulkowicz, M.d, M.D
Psychiatry — Payments: $476,134
Psychiatry $476,134
Dr. Ralph Aquila, M.d, M.D
Psychiatry — Payments: $327,213
Psychiatry $327,213
Leonardo Vando, Md, MD
Psychiatry — Payments: $265,745
Psychiatry $265,745